

**Cc:** Kate Guyton[GuytonK@iarc.fr]  
**To:** Isabelle Baldi[Isabelle.Baldi@isped.u-bordeaux2.fr]; Aaron Blair[blaira@exchange.nih.gov]; GMC24@columbia.edu[GMC24@columbia.edu]; Egeghy, Peter[Egeghy.Peter@epa.gov]; Forastiere, Francesco[f.forastiere@deplazio.it]; Lin Fritschi[lin.fritschi@curtin.edu.au]; Jahnke, Gloria (NIH/NIEHS) [E][jahnke@niehs.nih.gov]; Bill Jameson[drjameson@embarqmail.com]; Kromhout, J. (Hans)[h.kromhout@uu.nl]; frank lecurieux[frank.lecurieux@echa.europa.eu]; Martin, Matt[Martin.Matt@epa.gov]; John McLaughlin[John.McLaughlin@oahpp.ca]; Teresa Rodriguez[teresar66@gmail.com]; Matthew Ross[MRoss@cvm.msstate.edu]; Rusyn, Ivan[IRusyn@cvm.tamu.edu]; Consolato Sergi[biotechlab@gmail.com]; Mannetje, Andrea[A.Mannetje@massey.ac.nz]; Lauren Zeise[lxzeise@gmail.com]  
**From:** Chris Portier  
**Sent:** Mon 11/9/2015 11:05:19 AM  
**Subject:** IARC Monograph vol 112- EFSA Review of Glyphosate  
[IARCWG112ResponseV2.docx](#)  
[BFRGlyphosateAddendum.pdf](#)

Dear all,

This week, the European Food Safety Agency (EFSA) will release their reassessment of glyphosate. In this review, they will conclude that glyphosate has no carcinogenic potential. This creates two problems as I see it. The first is that this weakens the strength of the IARC Monograph Program to stimulate change in how some of these agents are reviewed and addressed. The second is that it suggests we did not do our assessment adequately and that, had we seen all of the data they saw, we would have gotten a different answer. I do not intend to let this happen.

The German Federal Institute for Risk Assessment (BfR) was the lead country agency in drafting the reassessment report. This report was drafted prior to the IARC review. In August of this year, following the release of the full Monograph on glyphosate, the BfR drafted an Addendum to their report that specifically addresses the Monograph review. I have decided to draft a letter that I intend to try to get published in Carcinogenesis that addresses the points made by the BfR in their review. Failing my ability to get this into Carcinogenesis, EHP or some other Journal, I intend to send it as an open letter to the European Commission. I am enclosing both the BfR Addendum and my response for you to look over. I would like as many members of the Working Group to be co-authors on this as possible. If you wish to see changes made to the letter I can certainly work on that. If you are uncomfortable signing on to such a letter, I can appreciate that as in my previous job this would have been impossible. Please let me know by Friday November 13 if you can or cannot join me in this endeavor.

Sincerely,

Christopher Portier